These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

159 related items for PubMed ID: 15515718

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. [Comment on: Volz A, Monsch A.U., Zahno A., Wettstein A., Stähelin H.B., Grünig R.: What did Alzheimer disease cost Switzerland in 1998? A preliminary analysis].
    Marko P.
    Praxis (Bern 1994); 2000 Jul 13; 89(27-28):1165-6. PubMed ID: 10959206
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Study notes huge costs associated with Alzheimer's disease.
    Levenson D.
    Rep Med Guidel Outcomes Res; 2002 Feb 22; 13(4):7-9. PubMed ID: 12434776
    [No Abstract] [Full Text] [Related]

  • 28. [Early diagnosis and therapy of Alzheimer dementia. Careful documentation prevents degeneration].
    Kohler J, Riepe MW, Jendroska K, Pilartz H, Adler G, Berger FM, Calabrese P, Frölich L, Gertz HJ, Hampel H, Haupt M, Mielke R, Paulus HJ, Zedlick D.
    MMW Fortschr Med; 2002 Nov 21; 144(47):53-4. PubMed ID: 12532523
    [No Abstract] [Full Text] [Related]

  • 29. Opportunities for improving managed care for individuals with dementia: Part 1--The issues.
    Fillit H, Knopman D, Cummings J, Appel F.
    Am J Manag Care; 1999 Mar 21; 5(3):309-15. PubMed ID: 10351027
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Economic evaluation of donepezil in moderate to severe Alzheimer disease.
    Feldman H, Gauthier S, Hecker J, Vellas B, Hux M, Xu Y, Schwam EM, Shah S, Mastey V, Donepezil MSAD Study Investigators Group.
    Neurology; 2004 Aug 24; 63(4):644-50. PubMed ID: 15326236
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Pharmacological therapy for people with Alzheimer's disease: the balance of clinical effectiveness, ethical issues and social and healthcare costs.
    Ballard C, Sorensen S, Sharp S.
    J Alzheimers Dis; 2007 Aug 24; 12(1):53-9. PubMed ID: 17851194
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. The economic consequences of Alzheimer's disease in the context of new drug developments.
    Knapp M, Wilkinson D, Wigglesworth R.
    Int J Geriatr Psychiatry; 1998 Aug 24; 13(8):531-43. PubMed ID: 9733334
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.